Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. - Wikidata - awgldk - TriplyDB

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.

http://www.wikidata.org/entity/Q36373455

about

A review of omalizumab for the management of severe asthma Recent advances in understanding and managing asthma Key paediatric messages from Amsterdam Pathogenic CD4+ T cells in patients with asthma.Immune Responses in Rhinovirus-Induced Asthma Exacerbations.The immunology of asthma: Asthma phenotypes and their implications for personalized treatment.Disaggregating asthma: Big investigation versus big data.How Much Asthma Is Atopic in Children?Mechanisms Mediating Pediatric Severe Asthma and Potential Novel Therapies.Cutting Edge: Critical Role of Glycolysis in Human Plasmacytoid Dendritic Cell Antiviral Responses.IFN Deficiency in Asthma Attacks. Is Restoring Toll-like Receptor-7 Expression a New Treatment Approach in Severe Asthma?dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies.Effects of Allergic Sensitization on Antiviral Immunity: Allergen, Virus, and Host Cell Mechanisms.The contributions of allergic sensitization and respiratory pathogens to asthma inception.Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?Asthma in Urban Children: Epidemiology, Environmental Risk Factors, and the Public Health Domain.Treatment of allergic children - Where is the progress (for the practicing allergist)?Advances in the treatment of virus-induced asthma.Update on Potential Therapies for IgE-Mediated Food Allergy.Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.Microbes, allergic sensitization, and the natural history of asthma.New Insights into Cockroach Allergens.Prospects for new and emerging therapeutics in severe asthma: the role of biologics.Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells.Asthma Exacerbations: Pathogenesis, Prevention, and Treatment.Eosinophilic and Non-Eosinophilic Asthma.Enhanced Plasmacytoid Dendritic Cell Antiviral Responses After Omalizumab.Asthma Attacks in Children: Does Blocking IgE Reduce Rhinoviral Infections?Effects of Omalizumab on Rhinovirus Infections, Illnesses and Exacerbations of Asthma.Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index.Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells.Allergy in severe asthma.Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?Anti-IgE Treatment for Disorders Other Than Asthma.Virus-triggered exacerbation in allergic asthmatic children: neutrophilic airway inflammation and alteration of virus sensors characterize a subgroup of patients.Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation.Novel therapeutic approaches to simultaneously target rhinovirus infection and asthma/COPD pathogenesis.An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases.Autoimmune polyendocrine syndrome type 2 in patient with severe allergic asthma treated with omalizumab.Advances in environmental and occupational disorders in 2016.

P2860

Q26741315-7780C518-CED3-4905-8BC8-35619F526060 Q28077915-C72CA97F-D23E-437C-89EF-3BAF067AC6E1 Q28596669-AB8DD135-22E3-478D-B95E-1CE48FAF81CA Q30252507-518735BE-FE25-4E81-875C-F8C39BB31C64 Q30275562-5EC56AE7-F5D8-48CE-B19D-6538CB3B9D2C Q30276175-448491E0-CD55-4793-87EF-BB34FA89097E Q31143790-BBE8FB6C-05E6-4B3A-A7A9-85A975EF1966 Q33729348-C91F6FAE-AD33-49F2-821A-FB4D6B1FB29E Q33871749-3E6E3EEE-0457-494D-8B97-9D52C6ED19B0 Q36600894-DE245DEF-8FC4-42BC-946E-3213B2A62B40 Q37125528-A1152734-D4EC-49B7-B4A4-8D3AA6B58CE5 Q38715930-8E20345E-4CA2-4994-918A-D07DAE1C272A Q38753828-01847D0D-6715-413B-AD31-6CD6AB60DAC7 Q38762750-37E83ADB-DB4A-4AC0-A65E-3100F48F7B4F Q38785897-3A9DD258-7CDE-4EBF-82FD-8425F1636A4B Q38793169-F2BA7530-2649-420D-A4EA-7518CDCED288 Q38809512-629442CA-9F39-4D94-A243-A7A7438D5513 Q38810784-2218E99C-FF13-4C17-AAFF-E52DE4BEECCA Q38970557-E636C2B7-63F2-46FC-A6E2-53FA0A75264C Q38982481-4FBFB42E-9891-4DD6-971F-8F13FF6C6FE3 Q39058913-26AA9057-592E-4C63-B626-377DE73A0747 Q39249999-1ACC956E-683F-46C7-BD47-1D27708CDC1A Q39278773-58205680-DB99-4610-AC96-08A204BE264B Q39402881-3F24BD2E-F0E7-45F4-90F7-4C0E10543842 Q39423972-EB07FE54-9342-4C6B-9987-32EA09206859 Q40046428-3ED8E3AD-CCD3-43B4-A1DB-CF293F949C8B Q40058577-F946D99A-574F-4CCB-A7D1-19926019E16C Q40162103-3BBCE2FF-9D69-4CA6-AE05-9CAD4FCEC099 Q40162127-02E181B8-64A6-47C4-868F-0A438112BE19 Q40317082-27456326-31F0-43AC-B434-0DB17D40B80C Q40347024-184B8625-89A3-4EA0-95E9-927176F94708 Q40488845-8E3319DC-28B2-49D7-8C8F-F6C0C25CE52E Q41633977-5D6678C4-D2F1-47AF-8DC4-3F9A54B184BF Q42091038-180E5294-1E0F-40C4-A4A1-DE8909D10011 Q45324856-271651C1-D2DD-40F9-B13A-69F76A9B382E Q45898148-998DCBDB-8A14-41D7-8C16-B8BA434EE490 Q46117915-18139C1E-1CCE-4F9B-A9F0-DE4B83443B94 Q47146658-2BFDDC25-4FBE-4716-9848-305AEC5C523C Q47557832-22778BCE-FC63-4698-B5A4-C02DE556CB8D Q47596939-6DD1806B-815F-4A2D-B3C4-E6E0C72FE000

P2860

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.

http://www.wikidata.org/entity/Q36373455

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Preseasonal treatment with eit ...... ent fall asthma exacerbations.

@ast

Preseasonal treatment with eit ...... ent fall asthma exacerbations.

@en

type

label

Preseasonal treatment with eit ...... ent fall asthma exacerbations.

@ast

Preseasonal treatment with eit ...... ent fall asthma exacerbations.

@en

prefLabel

Preseasonal treatment with eit ...... ent fall asthma exacerbations.

@ast

Preseasonal treatment with eit ...... ent fall asthma exacerbations.

@en

P1433

Q36373455-1F34D5BB-79B7-4998-86CF-00D289593E73

P1476

Q36373455-EAFA823C-251B-4C3A-9DC2-784FEEDED26B

P2093

Q36373455-08728E4E-BAD9-450D-B4DF-C9F4B19E5812

Q36373455-12A977A6-4B21-4AE2-9A68-44F9D0DDBCA8

Q36373455-16394D4B-98D6-4A13-8170-6E959C91D75F

Q36373455-2597A4CA-12C2-47E4-B00A-528C18D5D8E7

Q36373455-440AB1C4-1B2B-437D-8756-B5E3E86B0C4F

Q36373455-61B3CC1C-7957-4A99-983B-EB3302AFFEB3

Q36373455-6A4CDF44-6364-4FFF-A967-A3B983D598A2

Q36373455-7964ED1D-291B-41B4-8928-283A26E08EF6

Q36373455-7C566DEF-89E5-4D16-BDC3-42BCE9180B3A

Q36373455-9DE3D1AA-AC55-47E2-8969-2ABF58B05E42

P2860

Q36373455-07DC37F0-5209-4CDA-929F-BB9E4589E9DD

Q36373455-180542A7-F8DF-4B8D-8E0C-04C869C9403A

Q36373455-1BA4967F-EADA-4467-BD8A-3BB0EF6E1430

Q36373455-1C06E9E9-8167-47A0-AD0D-1C8097405824

Q36373455-1E5349BE-F906-48C4-8312-D17A965DB10C

Q36373455-20F74EF2-FB6C-4D03-94F6-B91792C5F8C3

Q36373455-225DDCDD-60BB-4C22-B973-ADF2683E1F31

Q36373455-2AE1C7F3-C325-4DC7-B711-E2CC43FDE1C2

Q36373455-45730B19-C85C-4A2D-BD30-3403617871AA

Q36373455-50198DBD-6A42-4985-9B32-4CE0B388E087

P304

Q36373455-3B09C531-3F87-4B81-AB67-2EB7A13F7E98

P31

Q36373455-5B733A0F-B16C-42B3-AC29-264866AE5B0A

P356

Q36373455-058FD59A-4350-42E5-A0E1-B03B629198CD

P407

Q36373455-768DA6E1-9D7E-4E13-8365-717888236DF7

P433

Q36373455-9C7F7AC4-2795-410F-B51E-D78DC6CA5207

P478

Q36373455-E22BE4C5-455B-494A-A709-ACBAEC21B45D

P50

Q36373455-02DAA952-0DB2-41DE-9334-E130A45B1967

Q36373455-377E5059-35F4-4AA3-BA64-27C3FB82081A

Q36373455-3C939940-8499-49A0-8A9A-8EAE3BAD3D5F

Q36373455-A3C57697-6BE9-4403-A7FA-CE46DAEFB489

Q36373455-FF1DCFAF-DFFB-4575-B953-E18C8C18717F

P577

Q36373455-DB2D6121-C7EB-46DD-A3AE-6C5D057DB74C

P5875

Q36373455-1B2B5B7A-2FC2-4923-8253-4F4D89010DE4

P698

Q36373455-1AB0CBEC-F664-48A8-9E17-664691290EE5

P921

Q36373455-2481B872-7329-4733-8FB9-AC9EF7444310

P932

Q36373455-6A249D24-37F4-4870-B5DD-647F981A5C62

P356

J.JACI.2015.09.008

P1433

The Journal of Allergy and Clinical Immunology

P1476

Preseasonal treatment with eit ...... ent fall asthma exacerbations.

@en

P2093

Agustin Calatroni

http://www.w3.org/2001/XMLSchema#string

Andrew H Liu

http://www.w3.org/2001/XMLSchema#string

Carolyn M Kercsmar

http://www.w3.org/2001/XMLSchema#string

Christine A Sorkness

http://www.w3.org/2001/XMLSchema#string

Edward M Zoratti

http://www.w3.org/2001/XMLSchema#string

Jacqueline A Pongracic

http://www.w3.org/2001/XMLSchema#string

James E Gern

http://www.w3.org/2001/XMLSchema#string

Jeremy J Wildfire

http://www.w3.org/2001/XMLSchema#string

Kristine A Grindle

http://www.w3.org/2001/XMLSchema#string

Meyer Kattan

http://www.w3.org/2001/XMLSchema#string

P2860

Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial

Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007

High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus

Asthma outcomes: exacerbations

Improved molecular typing assay for rhinovirus species A, B, and C.

A trial of clarithromycin for the treatment of suboptimally controlled asthma.

Role of viral respiratory infections in asthma and asthma exacerbations

Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.

P304

1476-1485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACI.2015.09.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

Gurjit Khurana Hershey

William W Busse

Stanley J Szefler

P577

2015-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283447720

http://www.w3.org/2001/XMLSchema#string

P698

26518090

http://www.w3.org/2001/XMLSchema#string

P921

P932

4679705

http://www.w3.org/2001/XMLSchema#string